Pronethalol
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
1-(naphthalen-2-yl)-2-(propan-2-ylamino)ethanol | |
| Clinical data | |
| Legal status |
|
| Routes of administration | Oral |
| Identifiers | |
| CAS Number | 51-02-5 |
| ATC code | None |
| PubChem | CID 4930 |
| ChemSpider | 4761 |
| UNII | XBP4RT1IMQ |
| ChEMBL | CHEMBL16476 |
| Chemical data | |
| Formula | C15H19NO |
| Molar mass | 229.32 g/mol |
| Chirality | Racemic mixture |
| |
Pronethalol (Alderlin, Nethalide) was an early non-selective beta blocker clinical candidate. It was never used clinically due to carcinogenicity in mice, which was thought to result from formation of a carcinogenic naphthalene epoxide metabolite.[1]
See also
References
| ||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Friday, February 26, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
